
Superpower peptides available for pre-order. Get first access.

Peptide science
What is the GLOW peptide blend (KLOW)?
GLOW is a research-chemical blend of GHK-Cu, BPC-157, and TB-500; KLOW adds KPV. No study has tested either blend, and no ingredient is FDA-approved.
Quick answer
The GLOW blend combines GHK-Cu, BPC-157, and TB-500; KLOW adds KPV. No study has tested either blend, and none of the four ingredients is FDA-approved. A 2026 scoping review of six such peptides, three of them in GLOW, found 67% of publications used animal models. Of the four ingredients, a draft HHS policy of October 30, 2026 covers only single-ingredient BPC-157, TB-500, and KPV, so both blends fall outside it.
- Published
- April 18, 2026
- Last updated
- November 12, 2026
Key takeaways
- What it is: The GLOW peptide blend is an injectable mix of GHK-Cu, BPC-157, and TB-500, and KLOW adds KPV.
- Evidence: Each ingredient has been studied separately, mostly in animal models1.
- FDA status: None of the ingredients is FDA-approved. Under a draft HHS policy published October 30, 20262, HHS does not intend to take enforcement action on single-ingredient BPC-157, TB-500, or KPV compounded by prescription. Neither blend nor injectable GHK-Cu is covered.
- Availability: GLOW and KLOW are sold in a gray market largely outside regulatory oversight3, and Superpower does not offer or sell them.
What is the GLOW peptide blend?
GLOW is a product name for an injectable blend of three peptides: GHK-Cu, BPC-157, and TB-500. Sellers also use the names "GLOW blend" and "GLOW stack." The GLOW name is a market label with no standard formulation, so doses, ratios, and purity vary by seller.
GLOW contains GHK-Cu, but the injectable blend differs from copper-peptide skin care, one of many topical peptides in skin care. GHK-Cu is widely used in anti-wrinkle cosmetic products4, though clinical studies of topical GHK are scarce.
Add a fourth peptide, and GLOW becomes KLOW.
GLOW vs. KLOW: how the two blends differ
KLOW is GLOW plus KPV, which makes it a four-peptide blend. KPV is a tripeptide of lysine, proline, and valine, a fragment of alpha-melanocyte-stimulating hormone5 (alpha-MSH), which the pituitary makes. Much of alpha-MSH's anti-inflammatory activity in animal models6 has been attributed to KPV.
KLOW shares GLOW's other three ingredients, so every open question about GLOW applies to KLOW, plus those a fourth compound raises.
The three GLOW blend ingredients and their evidence
Each GLOW ingredient has its own research record. In a review of six such peptides, 67% of publications used animal models1, and claimed musculoskeletal benefits remain unsubstantiated by current human trials1.
GHK-Cu is the tripeptide glycyl-histidyl-lysine bound to copper, linked in cell and animal models to collagen and elastin production during tissue remodeling7. BPC-157 is a synthetic 15-amino-acid gastric peptide8 whose research is almost all animal and cell work, with 35 of 36 orthopaedic studies preclinical9. TB-500 is not thymosin beta-4 itself but a product built on an acetylated copy of residues 17 to 2310. That stretch of thymosin beta-4 is tied to actin binding and cell migration11.
Each of those records was built one compound at a time.
What the evidence says about the blend itself
No published study, in people or animals, has tested GHK-Cu, BPC-157, and TB-500 together, with or without KPV.
The closest research gave BPC-157 and TB-500 to rats with Achilles-tendon injuries, and the combination added no benefit over either alone20. That exploratory rat study left out GHK-Cu and KPV.
A blend also raises open questions about interactions, the ratios sold, and stability, since peptides are often unstable in aqueous solutions21. Regulators, too, assess each ingredient on its own.
FDA status of GLOW and KLOW ingredients
None of GLOW's or KLOW's ingredients is FDA-approved. On October 30, 2026, HHS published a draft enforcement-discretion policy2 covering six peptides, including BPC-157, TB-500, and KPV15. HHS does not intend to take enforcement action against state-licensed pharmacies compounding them with a patient-specific prescription. The policy's conditions limit each product to one active ingredient15, so GLOW and KLOW fall outside it. Injectable GHK-Cu is not among the six.
The non-binding draft approves no peptide15 and adds none to the 503A bulks list. HHS may revisit the interim policy2.
FDA lists BPC-157, TB-500, injectable GHK-Cu, and KPV as nominated but withdrawn13 from its significant-safety-risk category. The nominators withdrew them, so the move was not an FDA finding that they are safe. Non-injectable GHK-Cu is set to return to Category 114, where BPC-157, TB-500, and KPV do not appear.
At its July 23-24, 2026 meeting22, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding15 BPC-157, TB-500, and KPV to the bulks list. Those votes are non-binding, and a GHK-Cu review is planned before the end of February 202723. None of these steps tested the safety of a blend.
GLOW's safety evidence
No study has measured the safety of GLOW or KLOW. For the unapproved peptides inside them, rigorous human safety data are scarce3. FDA has flagged a risk of immune reactions13 to BPC-157, TB-500, and injectable GHK-Cu. FDA also found limited or no human safety information for the ingredients.
Peptides sold outside regulated channels add risks of contamination, manufacturing impurities, and inaccurate dosing24, so each compound's evidence deserves a close read.
Where can I learn about peptides?
Superpower’s peptide library separates a marketed blend like GLOW from the research and regulatory record of each peptide inside it. Every guide is written and fact-checked by a team of health journalists and licensed clinicians.
Readers who want the chemistry behind terms like tripeptide, fragment, and copper-binding peptide can explore the science behind peptides.
Important safety information
GLOW and KLOW are not approved by the FDA for any medical use. They are research-chemical blends, and products sold under those names are labeled not for human use.
GLOW contains GHK-Cu, BPC-157, and TB-500. KLOW adds KPV. The research on these ingredients is preliminary and comes mostly from cell-culture and animal studies. No human trial of either blend exists, and their safety and effectiveness in people have not been established.
Superpower does not offer, sell, prescribe, or facilitate GLOW, KLOW, or injectable GHK-Cu. Evidence is preliminary, and no safety or effectiveness claims are made.
Products sold through unregulated channels have no verified purity, potency, or sterility. This page is educational and does not constitute medical advice. Talk with a licensed clinician about any question about your health.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to the GLOW or KLOW peptide blends. No ingredient in either blend is FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.